BioVie: Funding, Investors & Team (Sep 2026)

Focusing on Finding Solutions for Healthier Brain, Memory, and Movement. Our neurology strategy is centered at what we understand to be the nexus of biochemistry, cellular energetics, and neuroprotection, enabling us to explore the potential of our pipeline molecules to decrease inflammation, enhance glucose utilization, protect neurons, and facilitate energy transfer within the central nervous system, ultimately leading to improvements in memory and movement, and a healthier brain. Our lead Neuroscience molecule (NE3107) is currently being investigated in human clinical studies to assess its hypothesized impact on both Alzheimer’s and Parkinson’s. Exploring the possibilities of improved outcomes, fewer medical burdens, and more time at home. In our cirrhosis studies, we are working to learn if our exploratory technology can help individuals who have been diagnosed with cirrhosis-related ascites (fluid that builds up inside the abdomen) to be more comfortable, to require fewer or less frequent medical procedures to drain ascites fluid, and to see if the treatment can help people with ascites to live outside of the hospital for longer periods of time. BioVie is currently investigating BIV-201, a novel formulation of terlipressin, in human clinical trials. In BioVie’s studies of BIV-201, the exploratory medication is provided as a continuous infusion formulation delivered by a small, portable pump that the user can wear while engaging in typical tasks and activities at home. For more information about BioVie and our current studies, please visit our website https://bioviepharma.com/

BioVie has raised $18.7M across 2 rounds on record. The most recent is an undisclosed round of $12.0M announced in Aug 2025.

BioVie's most recent funding round on record is an undisclosed round of $12.0M, announced in Aug 2025.

FundedIQ lists O E Campbell (Founder) at BioVie.

BioVie is based in Beverly, Massachusetts, United States.

BioVie is in the 11-50 employee band.

BioVie's latest round of $12.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.